NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke Conference (WSC). According to the latest data, the administration of edaravone dexborneol (Sanbexin®) in patients with acute ischemic stroke (AIS) before receiving endovascular thrombectomy significantly improved neuro-function recovery and reduced disability from stroke.
Presented as a WCS late-breaking oral presentation by Professor Yongjun Wang from Beijing Tiantan Hospital, the study entitled "Treatment of Acute ischemic Stroke with Edaravone dexborneal 2" ("TASTE-2") has caught wide spread attention among neurology academic circle in the world.
Stroke is the leading cause of death and disability in adults in China, while AIS accounts for about 70% of all strokes. About 40% of AIS patients fall into the category of large vessel occlusion (LVO), a subtype of AIS with higher disability and mortality.
After stroke, reperfusion treatments (e.g., thrombolysis and thrombectomy) are used to restores blood supply to the brain as soon as possible. The endovascular thrombectomy (EVT), an important advance in reperfusion therapy in recent years, can achieve recanalization in about 70% to 90% of patients with the LVO stroke, but only half of these patients achieve favorable brain function recovery A significant proportion of the patients who received EVT remain disabled to varying degrees after 90 days of treatment.
TASTE-2 study is a multicenter, double-blind, randomized, placebo-controlled clinical study. From March 2022 to May 2023, a total of 1362 AIS patients with a large-vessel occlusion (LVO) in the anterior circulation were enrolled. Patients were randomly allocated (1:1) to receive edaravone dexborneol (edaravone, 30 mg; (+)-dexborneol, 7.5 mg) or placebo prior to EVT and continued twice a day over a consecutive period of 10-14 days. As a primary efficacy outcome, 379 (55.0%) patients in the edaravone dexborneol group and 333 (49.6%) in the placebo group achieved a mRS 0-2 at day-90 (odds ratio [OR] 1.24, 95% CI 1.00-1.54; risk ratio [RR] 1.11, 95% CI 1.00-1.23). All safety outcomes were similar between both groups. This suggests that Edaravone dexborneol could improve the favorable functional outcome at 90 days in AIS patients within 24-hour of symptom onset who underwent EVT.
Sanbexin® (Edaravone dexborneol Concentrated Solution for Injection) is a multi-targeted brain cell protection agent developed by Simcere Pharmaceutical Co., Ltd, and is the only approved innovative drug in the field of stroke treatment worldwide since 2015. Composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, the drug can significantly reduce brain cell injury or impairment caused by AIS.
According to the recommendations of the Stroke Academic Roundtable Meeting (STAIR), brain cytoprotectants can reduce ischemic brain injury, especially when combined with thrombectomy. The scientific community has also been working on brain cytoprotective agents for stroke treatment for decades. However, due to the complexity of stroke pathophysiology, single-target drugs have been found to have limited efficacy and difficult to be developed clinically.
On the other hand, the clinical study of multi-target brain cytoprotectants continue to progress. Previously, the TASTE study led by Professor Yongjun Wang's team in Beijing Tiantan Hospital and the TASTE-SL study led by Professor Dongsheng Fan in Peking University Third Hospital confirmed the efficacy of edaravone dexborneol injection and sublingual tablets in AIS patients who do not receive reperfusion treatment. The latest results of the TASTE-2 study provide key clinical medical evidence for Sanbexn® as a multi-target brain cell protection strategy combined with reperfusion in the treatment of acute ischemic stroke. Sanbexin® is expected to be used as a concomitant drug for endovascular treatment such as thrombectomy, particularly before reperfusion, to further improve the effect of stroke treatment and reduce stroke disability.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
World Stroke Congress | TASTE-2 significantly reduces stroke disability
JAKARTA, Indonesia, Oct. 30, 2024 /PRNewswire/ -- Evermos is proud to announce its latest achievement as the winner of the 2024 UN Women Indonesia WEPs Awards in the "Gender-responsive Marketplace" category. In the same category, Cimory was awarded Runner Up 1, and PT Transjakarta received Runner Up 2, both recognized alongside Evermos. The 2024 UN Women Indonesia WEPs Awards mark a significant milestone in Evermos' journey to empower and support women's economic independence through an inclusive digital platform.
The UN Women WEPs Awards celebrate companies taking concrete steps to achieve gender equality in line with the Women's Empowerment Principles (WEPs). These principles consist of seven guidelines to help businesses create environments that foster women's empowerment in the workplace and the broader community. Moreover, this award aims to encourage more companies to incorporate gender-inclusive frameworks into their operations and strengthen a culture of inclusivity.
"We are truly honored by this recognition from UN Women, which underscores our ongoing dedication to gender equality and women's empowerment at Evermos. This commitment is at the heart of everything we do." said Ilham Taufiq, Co-founder & Acting CEO of Evermos. "This award is not just an acknowledgment of our efforts but also a reminder of the work that still lies ahead for us to empower more women across Indonesia to achieve economic independence."
Since it first started, Evermos has empowered over 1,000,000 individuals or resellers, 86% of whom are women. Through its platform, Evermos encourages economic independence, especially among women living in areas with limited job opportunities, by providing employment, fostering entrepreneurship, and offering free access to business training. The average monthly income reported by Evermos' resellers is approximately USD 239.45, surpassing the national average of USD 195.50, thus contributing to greater economic stability for their families.
Evermos also supports the personal development of its resellers, the majority of whom are women. From the moment they join Evermos, resellers are encouraged to connect with nearby Evermos reseller communities. There are currently over 1,900 Evermos reseller communities across Indonesia. Within these communities, resellers receive guidance, training, and support to help them grow into successful entrepreneurs. Evermos regularly organizes meetings that include training sessions and networking activities to strengthen the bonds between resellers within their communities. High-performing resellers also have the opportunity to "level up" by taking on the role of Reseller Coordinator (KORI), or community leader. In this leadership position, they receive incentives, additional training, and extra support from Evermos to further enhance their skills.
Evermos' success is not just the story of one company; it also reflects UN Women's mission to recognize and promote innovations that drive positive change. This award adds to Evermos' growing list of accomplishments and further establishes its role as a key player in developing the local entrepreneurship ecosystem.
About Evermos
Evermos is a connected commerce platform that supports local entrepreneurs in starting and growing their businesses by providing a distribution network in tier 2 and 3 cities, as well as integrated commerce services. It serves as a one-stop platform offering comprehensive support for entrepreneurs, from local brand owners and resellers to pro-sellers. Evermos provides free entrepreneurial training to anyone within its reseller network, supporting their success regardless of gender, educational background, geographical location, or income level.
Founded in November 2018, Evermos has built the largest reseller-based connected commerce network in Indonesia, with over 967,000 active sellers and 6,400 SME partners across the country. To date, Evermos has received numerous industry accolades, including the Forbes Asia 100 to Watch in the Asia-Pacific region, the UN Women Indonesia Women's Empowerment Principles (WEPs) Awards in 2022 & 2024, the 2024 Nikkei Awards, and membership in the global Endeavor Entrepreneur network. Evermos is also a member of the World Economic Forum's Global Innovators Community, a select group of the world's most promising start-ups and scale-ups leading in technological innovation and ethical business models.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Evermos Wins 2024 UN Women WEPs Awards for Its Dedication to Empowering Women's Communities through an Inclusive Digital Platform
